7789-64-2 Purity
99.99%
If you have any other questions or need other size, please get a quote.
Reference: [1]Current Patent Assignee: BRISTOL-MYERS SQUIBB CO - US2016/289171, 2016, A1
Location in patent: Paragraph 0678
[2]Current Patent Assignee: CURIA INC - US2008/255114, 2008, A1
Location in patent: Page/Page column 17
[3]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - US2012/28969, 2012, A1
Location in patent: Page/Page column 80
Reference: [1]Current Patent Assignee: Novartis (w/o Sandoz); NOVARTIS AG - US2012/28969, 2012, A1
[2]Current Patent Assignee: BRISTOL-MYERS SQUIBB CO - US2016/289171, 2016, A1
Reference: [1]Location in patent: scheme or table
Yang, Zhicai; Fairfax, David J.; Maeng, Jun-Ho; Masih, Liaqat; Usyatinsky, Alexander; Hassler, Carla; Isaacson, Soshanna; Fitzpatrick, Kevin; Deorazio, Russell J.; Chen, Jianqing; Harding, James P.; Isherwood, Matthew; Dobritsa, Svetlana; Christensen, Kevin L.; Wierschke, Jonathan D.; Bliss, Brian I.; Peterson, Lisa H.; Beer, Cathy M.; Cioffi, Christopher; Lynch, Michael; Rennells, W. Martin; Richards, Justin J.; Rust, Timothy; Khmelnitsky, Yuri L.; Cohen, Marlene L.; Manning, David D.
[Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 22, p. 6538 - 6541]
* For details of the synthesis route, please refer to the original source to ensure accuracy.